Literature DB >> 12510773

cDNA array analysis of SPARC-modulated changes in glioma gene expression.

William A Golembieski1, Sandra A Rempel.   

Abstract

We have demonstrated that secreted protein acidic and rich in cysteine (SPARC) is highly expressed in human gliomas and it promotes glioma invasion and delays tumor growth in vitro and in vivo. cDNA array analyses were performed to determine whether SPARC, which interacts at the cell surface, has an impact on intracellular signaling and downstream gene expression changes, which might account for some of its effects on invasion and growth. Using a doxycycline (dox)-controlled gene expression system, two cDNA array analyses were performed using a parental U87T2 clone (-SPARC) transfected with the dox-controlled transactivator and a U87T2 parental-derived SPARC-transfected clone, A2b2 (+SPARC). Array analysis performed between the parental and the SPARC-transfected clone (-dox) identified 13 upregulated genes and 14 downregulated genes. With the exception of PAI-1 and MMP2, the identified genes are novel with respect to SPARC's mechanism of action. Array analysis performed using the SPARC-transfected clone ( +/- dox) identified 2 types of gene regulation; one reversible upon SPARC suppression, the other irreversible. Two of the SPARC-induced genes, BIGH3 (irreversible by dox) and PAI-1 (reversible by dox) were further studied in additional SPARC-transfected clones, human astrocytoma tissues, and human glioma cell lines by RT-PCR and Northern blot analyses. The results indicate that: (1) the array results were validated, (2) the dox regulation was validated, and (3) the differential expression identified by the array analyses was present between normal brain and in human astrocytoma tissues and cell lines. Therefore, we conclude that these cDNA array analyses provide candidate genes involved in SPARC-mediated effects on glioma cell cycle progression, signaling, and migration, and that SPARC may induce reversible and irreversible gene expression changes. Further investigation of these candidates may shed insights into SPARC's role in glioma cell proliferation and invasion, and potential use as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12510773     DOI: 10.1023/a:1021167211131

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.

Authors:  Y Jo; J Yeon; H J Kim; S T Lee
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes.

Authors:  S Lee; D E Solow-Cordero; E Kessler; K Takahara; D S Greenspan
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

3.  Distribution of osteonectin mRNA and protein during human embryonic and fetal development.

Authors:  S Mundlos; B Schwahn; T Reichert; B Zabel
Journal:  J Histochem Cytochem       Date:  1992-02       Impact factor: 2.479

4.  SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells.

Authors:  P Hasselaar; E H Sage
Journal:  J Cell Biochem       Date:  1992-07       Impact factor: 4.429

5.  A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: high SPARC secretion correlates with decreased migration on vitronectin.

Authors:  P M Menon; J A Gutierrez; S A Rempel
Journal:  Int J Oncol       Date:  2000-10       Impact factor: 5.650

6.  SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins.

Authors:  S A Rempel; W A Golembieski; J L Fisher; M Maile; A Nakeff
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

7.  Alteration of cell adhesion and cell cycle properties of ES cells by an inducible dominant interfering Myb mutant.

Authors:  N Iwai; K Kitajima; K Sakai; T Kimura; T Nakano
Journal:  Oncogene       Date:  2001-03-22       Impact factor: 9.867

8.  Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix.

Authors:  M D Gooden; R B Vernon; J A Bassuk; E H Sage
Journal:  J Cell Biochem       Date:  1999-08-01       Impact factor: 4.429

9.  Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1.

Authors:  T F Lane; M L Iruela-Arispe; E H Sage
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

10.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors.

Authors:  E W Raines; T F Lane; M L Iruela-Arispe; R Ross; E H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  17 in total

1.  Adenovirus-mediated coexpression of DCX and SPARC radiosensitizes human malignant glioma cells.

Authors:  Yuanyuan Xu; Lei Yang; Xin Jiang; Jiahua Yu; Jicheng Yang; Haowen Zhang; Guomei Tai; Xiaopeng Yuan; Fenju Liu
Journal:  Cell Mol Neurobiol       Date:  2013-07-12       Impact factor: 5.046

2.  PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Authors:  Stacey L Thomas; Ridwan Alam; Nancy Lemke; Lonni R Schultz; Jorge A Gutiérrez; Sandra A Rempel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

Review 3.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

4.  SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.

Authors:  Sateesh Kunigal; Christopher S Gondi; Meena Gujrati; Sajani S Lakka; Dzung H Dinh; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2006-12       Impact factor: 5.650

5.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

6.  SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells.

Authors:  Heather M McClung; Stacey L Thomas; Pamela Osenkowski; Marta Toth; Priya Menon; Avraham Raz; Rafael Fridman; Sandra A Rempel
Journal:  Neurosci Lett       Date:  2007-04-21       Impact factor: 3.046

7.  Screening feature genes of astrocytoma using a combined method of microarray gene expression profiling and bioinformatics analysis.

Authors:  Yong Cai; Xingming Zhong; Yiqi Wang; Jianguo Yang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

Review 9.  Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2012-08-21       Impact factor: 6.208

10.  SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion.

Authors:  Christopher K Yunker; William Golembieski; Nancy Lemke; Chad R Schultz; Simona Cazacu; Chaya Brodie; Sandra A Rempel
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.